menu
    • menu

    Company profile for Ovoca Bio

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing BP-101, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of BP-101, which has been submitted for mar...
    Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing BP-101, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of BP-101, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ovoca BioIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    17 Pembroke Street Upper Dublin 2 D02 AT22
    Telephone
    Telephone
    +353 1 661 9819
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ovocabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CRO issues dampen Ovoca Bio’s trial of female sexual desire drug
    CRO issues dampen Ovoca Bio’s trial of female sexual desire drug

    14 Jun 2023

    // Joseph Keenan FIERCE BIOTECH

    https://www.fiercebiotech.com/cro/cro-issues-dampen-ovoca-bios-drive-get-female-sexual-desire-drug-approved

    Joseph Keenan FIERCE BIOTECH
    14 Jun 2023
    Share Share
    Statement re Russian Business Operations
    Statement re Russian Business Operations

    07 Mar 2022

    // PRESS RELEASE

    https://otp.tools.investis.com/clients/uk/ovoca/rns/regulatory-story.aspx?cid=2552&newsid=1556697

    PRESS RELEASE
    07 Mar 2022
    Share Share
    Second Price Monitoring Extn
    Second Price Monitoring Extn

    23 Feb 2022

    // INVESTIS

    https://otp.tools.investis.com/clients/uk/ovoca/rns/regulatory-story.aspx?cid=2552&newsid=1553394

    INVESTIS
    23 Feb 2022
    Share Share
    Russian Marketing Authorisation for Orenetide
    Russian Marketing Authorisation for Orenetide

    22 Feb 2022

    // PRESS RELEASE

    https://otp.tools.investis.com/clients/uk/ovoca/rns/regulatory-story.aspx?cid=2552&newsid=1553003

    PRESS RELEASE
    22 Feb 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search